(RTTNews) - Liminatus Pharma, Inc. (LIMN), a biotechnology company developing immuno-oncology and cell therapy candidates, announced that it has regained compliance with Nasdaq's minimum bid price rule.
October NY world sugar #11 (SBV26 ) is up +0.46 (+2.63%) today, and December London ICE white sugar #5 (SWZ26 ) is up +7.40 (+1.47%). Sugar prices are moving higher today, with London sugar posting a 1-week high. Prices are trading sideways within a wide month-long range, between last Tuesday’s...
(RTTNews) - Mayne Pharma Group Ltd. (MYX.AX) announced that Sun Pharmaceutical Industries Ltd. (SUNPHARMA.NS) has agreed to settle U.S. Paragraph IV patent litigation concerning IMVEXXY and its associated FDA Orange Book-listed patents.
(RTTNews) - On Tuesday, Argenx SE (ARGX) announced that it will present new clinical, long-term and real-world data for VYVGART (efgartigimod) across Myasthenia gravis and Chronic inflammatory demyelinating polyneuropathy (CIDP), along with updates from its neuromuscular pipeline
Key PointsIt’s been a year of historic change at the nation’s central bank, with new Fed Chair Kevin Warsh kicking off only the fourth rate-hiking cycle of the 21st century on Sept. 16.
(RTTNews) - Zealand Pharma A/S (ZEAL.CO), a biotechnology company, on Wednesday announced the publication of new results from the Phase 3 ZUPREME-1 trial for Petrelintide in weight management. The data was published in The Lancet Diabetes and Endocrinology journal.
Fintel reports that on September 29, 2026, Scotiabank initiated coverage of Xcel Energy Inc. - Preferred Stock (NASDAQGM:XELLL) with a Sector Outperform recommendation. On the day of the coverage initiation, September 29, 2026, the stock's latest close was $20.96. This followed a
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK, 4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis.
(RTTNews) - Roche Holding AG (RHHBY), a healthcare company, announced two regulatory developments, with the U.S. FDA accepting its New Drug Application (NDA) for Fenebrutinib in relapsing multiple sclerosis and primary progressive multiple sclerosis under Priority Review.